By Kimberly Chin

 

A Fujifilm Holdings Corp. subsidiary will buy Atara Biotherapeutics Inc.'s T-cell operations and manufacturing facility for a $100 million upfront consideration as well as enter into a long-term supply agreement with the T-cell immunotherapy developer.

The Fujifilm subsidiary will keep the current manufacturing and quality staff at the Thousand Oaks, Calif., Atara said. The subsidiary will expand the use of the plant with plans to manufacture a broader portfolio of cell therapies, Atara said.

The companies have also entered into a supply agreement that could last 10 years. The Fujifilm subsidiary, a leading contract development and manufacturing organization, will enable Atara to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, Atara said.

The proceeds from the deal will be used to fund Atara's planned operations into the fourth quarter of 2023, it said.

Atara's shares rose 9.3% after hours to $16.66.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

January 26, 2022 17:29 ET (22:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Atara Biotherapeutics Charts.
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Atara Biotherapeutics Charts.